Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Therapeutics Development Initiative, 2010
    Metal Complexation with Levodopa to Improve Continuous Dopaminergic Stimulation

    Objective/Rationale:
    Our goal is to market a new levodopa/carbidopa orally-administered drug product with pharmacokinetics (PK) similar to that seen with direct infusion products. Currently, orally...

  • Therapeutics Development Initiative, 2010
    Novel, Selective and Potent Brain-penetrant Small Molecule Inhibitors of Cytosolic Hsp90

    Objective/Rationale:
    Our objective is to develop novel drug candidates as therapeutics for Parkinson's disease by selectively targeting and inhibiting the heat shock protein-90 (Hsp90) in the brain...

  • MJFF Research Grant, 2010
    Generation of Phosphospecific LRRK2 Antibodies

    Objective/Rationale:
    LRRK2 (Leucine-Rich Repeat Kinase 2) is a protein thought to be involved in regulating signaling pathways in cells. Mutations in the gene for LRRK2 are associated with some...

  • MJFF Research Grant, 2010
    Generation of PINK1 Antibodies

    Objective/Rationale:
    PINK1 (PTEN-Induced Kinase 1) is a protein involved in regulating signaling pathways in the energy “powerhouse” of cells, known as mitochondria. Mutations in the gene for PINK1 are...

  • Target Validation, 2010
    Gremlin-1, a Putative VTA-derived Neuroprotective Factor in Parkinson's Disease

    Objective/Rationale:
    We recently showed that certain brain neurons which are normally protected from Parkinson’s disease (PD) contain high levels of the developmental factor Gremlin-1. The goal of this...

  • Target Validation, 2010
    Treating Early Cognitive Impairments and Associated Movement Control Deficits by Stimulating alpha4beta2* nAChRs

    Objective/Rationale:
    Cholinergic systems decline early in PD and are hypothesized to contribute to cognitive impairments as well as to impairments in performing complex movements and postural...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.